Search Bar & Filters
Found 4 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating how the study medicine CagriSema helps adults living with obesity, with or without type 2 diabetes, lose weight. This clinical trial compares two different doses of CagriSema with semaglutide, a medicine already prescribed for weight loss. The study aims to understand the safety and effectiveness of CagriSema in reducing body weight over time. Participants are randomly assigned to receive one of three treatments CagriSema at dose level 1, CagriSema at dose level 2, or semaglutide. Each treatment is given once weekly as a subcutaneous injection over a 72-week period. The study lasts about 83 weeks in total to include all treatment and follow-up time. During the study, participants will have regular visits for assessments including body weight, body mass index, waist circumference, cholesterol levels, and blood sugar control. Questionnaires on physical function and quality of life will also be completed. Researchers will track any side effects and serious adverse events throughout the study and after treatment ends, monitoring safety for up to 80 weeks.
Actively Recruiting
Researchers are evaluating the effects of a medicine called survodutide on adults living with type 2 diabetes who have a body mass index BMI of 23 kgm2 or higher. The study aims to find out whether survodutide helps control blood sugar levels compared to a placebo. This phase III trial includes participants who manage their diabetes with diet and exercise, diabetes tablets, or insulin injections, reflecting different treatment backgrounds. Participants are divided into three parts based on their current diabetes treatment Part A includes those using diet and exercise only, Part B includes those on oral diabetes medications without insulin, and Part C includes those using insulin injections with or without diabetes tablets. Within each part, participants are randomly assigned to one of three groups placebo, low-dose survodutide, or high-dose survodutide. The medicine or placebo is injected under the skin once a week while participants continue their regular diabetes treatment. Over about 14 months, participants attend up to 12 in-person visits and receive at least 9 phone calls for monitoring. Doctors regularly check blood sugar levels using HbA1c tests and other laboratory tests, and monitor overall health and any changes. The main measure is the change in HbA1c from the start to Week 41, while additional outcomes include blood sugar levels, body weight, cholesterol, kidney function, and insulin dose changes. Results will compare survodutide groups with placebo to assess its impact on diabetes management.
Actively Recruiting
Researchers are evaluating zenagamtide, an oral medication, to determine its safety and effectiveness in helping adults with excess body weight lose weight. This phase 3 clinical trial compares zenagamtide against a placebo to understand its impact as part of a treatment for overweight and obesity. The study involves participants aged 18 and older who will be randomly assigned to different treatment groups. Participants will receive either one of five dose levels of zenagamtide or a placebo, both taken orally once daily. These treatments are combined with a reduced-calorie diet and increased physical activity to support weight loss efforts. The study treatment period lasts up to 76 weeks, during which participants follow the lifestyle changes alongside the medication or placebo. Throughout the study, participants will be monitored regularly to assess changes in body weight as the primary outcome, alongside secondary measures like waist circumference and systolic blood pressure. Safety and adherence will also be tracked. The total participation duration extends up to about 76 weeks, with ongoing evaluations to understand the treatment effects over this timeframe.
Actively Recruiting
Researchers are studying the safety and tolerability of switching from semaglutide to a new combined treatment called CagriSema in adults with type 2 diabetes. This phase 3 clinical trial evaluates three different dosing schedules of CagriSema in people who have been taking semaglutide once weekly. The goal is to understand how well participants tolerate this switch and monitor any side effects during the treatment period. Participants who have been treated with once-weekly semaglutide will switch to one of three regimens involving once-weekly doses of CagriSema. The first group will switch directly to dose 1 of CagriSema, the second group will start with dose 2 then switch to dose 1, and the third group will begin with dose 3, then move to dose 2, and finally dose 1. All doses are given by subcutaneous injection once weekly. The study lasts approximately six months for each participant. During the trial, participants will be monitored for treatment-emergent adverse events from the start of treatment through week 16 and up to week 22. Assessments include checking for episodes of low blood sugar confirmed by glucose measurements and gastrointestinal side effects that may cause participants to stop treatment. Participants will have regular visits to track safety and tolerability while receiving the study drug. The overall study duration for participants is about six months.